simeon bennett: potentially huge.f but you can imagine a cure for hiv being a multibillion-dollar opportunity. we are not talk about new drugs but the ones we already got, using the much earlier to treat patients in the early stages of infection. and so the likes of gilead and glaxosmithkline are investing in hiv cure research and really you can see it being a huge opportunity. manus: thank you for a heartening story on a day on pharmaceuticals. simeon bennett bloomberg health reporter. a cell of the financial times. receiving interest and potential buyers. for more now joined by manuel. where have i heard this story before? i heard it last year. they chatted. costly to run ft. is $1 billion right? manuel: this time around, they are trying to sell it. let's see if it goes through. we have seen it in the media industry this year quiet compared to other sectors like health care and telecom and technology. this is a trophy assets. manus: is it where it comes into the fray? manuel maigorri: exactly. media companies lookin